Latest News about BIIB
Recent news which mentions BIIB
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
October 25, 2023
Tickers
BIIB
From Benzinga
Stocks to own ahead of a rally that this $15 billion fund house says is coming soon
October 25, 2023
From MarketWatch
An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week
October 24, 2023
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 23, 2023
From Benzinga
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
October 18, 2023
Tickers
BIIB
From Benzinga
3 Struggling Stocks Investors Shouldn't Buy on the Dip
October 18, 2023
From Motley Fool
Quant Ratings Updated on 92 Stocks
October 17, 2023
From InvestorPlace
Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry
October 16, 2023
Tickers
BIIB
From Benzinga
From Benzinga
7 Low-Volatility Stocks to Buy if You’re a Concerned Investor
October 11, 2023
From InvestorPlace
From Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
From Benzinga
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
October 05, 2023
From Benzinga
Quant Ratings Updated on 74 Stocks
October 03, 2023
From InvestorPlace
From Benzinga
From Benzinga
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
September 22, 2023
From Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
September 15, 2023
Tickers
BIIB
From Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
September 09, 2023
From Motley Fool
From InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
September 06, 2023
From Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
From Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.